STOCK TITAN

Travere Therapeutics Inc - TVTX STOCK NEWS

Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.

Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare kidney, liver, and metabolic diseases. The company's key focus is the development of its investigational product candidate, sparsentan. This novel therapy is in late-stage development for treating focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can lead to end-stage kidney disease.

Travere Therapeutics has made significant strides in its mission, marked by several recent achievements. The company reported positive topline data from the pivotal phase-III PROTECT study of sparsentan in IgAN, showing a substantial reduction in proteinuria and potential long-term benefits in preserving kidney function. This led to the conditional marketing authorization of sparsentan under the brand name FILSPARI® in Europe and anticipated full approval in the U.S.

Additionally, Travere Therapeutics is advancing other innovative therapies. The company is exploring the potential of pegtibatinase as the first disease-modifying treatment for classical homocystinuria (HCU), with topline data expected in 2026.

Travere's strategic partnerships, such as with CSL Vifor, amplify its reach and impact. CSL Vifor has exclusive commercialization rights for sparsentan in Europe, Australia, and New Zealand. Together, these companies are dedicated to bringing promising treatments to patients worldwide.

The company's financial condition remains robust, supported by a strong pipeline and successful trials. Travere's commitment to the rare disease community is evidenced by its relentless pursuit of better treatment options and its collaborative efforts with patients, families, and caregivers.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.2%
Tags
-
-
Rhea-AI Summary

Travere Therapeutics (NASDAQ: TVTX) is set to release its first quarter 2023 financial results on May 4, 2023, following the close of U.S. markets. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on its business. Interested parties can access the information on the Investor page of Travere’s website. Travere Therapeutics focuses on developing therapies for rare diseases, emphasizing its commitment to supporting patients and families facing these challenges. This upcoming earnings release may provide insights into the company’s financial health and strategic direction, crucial for stakeholders and investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
conferences earnings
Rhea-AI Summary

Travere Therapeutics has announced the grant of inducement equity awards to five new employees, with a total of 30,000 restricted stock units (RSUs) issued on April 10, 2023. These RSUs, which are part of the 2018 Equity Incentive Plan, are specifically intended to attract new talent in accordance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule for these RSUs spans four years, with 25% vesting on each anniversary, contingent upon the employees maintaining their service with the company.

Travere Therapeutics is dedicated to developing therapies for rare diseases, focusing on patient needs and community involvement to improve treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
Rhea-AI Summary

Travere Therapeutics (TVTX) announced significant findings from the interim analysis of the Phase 3 PROTECT Study for FILSPARI™ (sparsentan), published in The Lancet. The data showed a mean reduction in proteinuria of 49.8% after 36 weeks of treatment with FILSPARI, contrasting sharply with a 15.1% reduction for irbesartan (p<0.0001). Moreover, 20.8% of patients on FILSPARI achieved complete remission, versus 7.9% for irbesartan (p=0.0005). The results indicate FILSPARI's potential for long-term benefits on kidney function and confirm its favorable safety profile, with adverse events comparable to irbesartan. Topline results for the study's confirmatory analysis are expected in Q4 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Travere Therapeutics (NASDAQ: TVTX) will participate in two upcoming conferences. The first is the Guggenheim Healthcare Talks scheduled for April 4, 2023, at 3:55 p.m. ET. The second is the BofA Securities 2023 Health Care Conference on May 10, 2023, at 3:40 p.m. PT. Live webcasts of both presentations will be available on the company's Investor page, and replays will be accessible for up to 30 days post-event. Travere is dedicated to developing therapies for rare diseases, working closely with patients and the healthcare community to address urgent treatment needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
conferences
Rhea-AI Summary

Travere Therapeutics (NASDAQ: TVTX) announced that interim efficacy and safety data from the Phase 3 PROTECT Study of FILSPARI™ (sparsentan) for IgA nephropathy (IgAN) will be presented at the ISN World Congress of Nephrology in Bangkok (March 30-April 2, 2023) and NKF Spring Clinical Meetings in Austin (April 11-15, 2023). FILSPARI has received U.S. accelerated approval to reduce proteinuria in IgAN patients at risk of rapid progression. The company will share findings on patient populations and long-term data from the DUET Study of sparsentan in focal segmental glomerulosclerosis (FSGS). Key presentations will highlight significant clinical trial results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags

FAQ

What is the current stock price of Travere Therapeutics (TVTX)?

The current stock price of Travere Therapeutics (TVTX) is $21.98 as of February 21, 2025.

What is the market cap of Travere Therapeutics (TVTX)?

The market cap of Travere Therapeutics (TVTX) is approximately 2.1B.

What is the primary focus of Travere Therapeutics?

Travere Therapeutics focuses on developing therapies for rare kidney, liver, and metabolic diseases.

What is sparsentan?

Sparsentan is an investigational product candidate being developed by Travere Therapeutics for treating FSGS and IgAN.

What recent achievements has Travere Therapeutics made?

Travere Therapeutics has reported positive topline data from the phase-III PROTECT study of sparsentan in IgAN and received conditional marketing authorization for sparsentan in Europe.

What are the indications for FILSPARI®?

FILSPARI® is indicated for reducing proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression.

Who are Travere Therapeutics' strategic partners?

CSL Vifor is a key strategic partner, holding exclusive commercialization rights for sparsentan in Europe, Australia, and New Zealand.

What is the potential significance of pegtibatinase?

Pegtibatinase has the potential to become the first disease-modifying treatment for classical homocystinuria, with topline data expected in 2026.

What are the key safety considerations for FILSPARI® therapy?

Safety considerations include monitoring for hepatotoxicity and embryo-fetal toxicity; the therapy is available only through a restricted program called the FILSPARI REMS.

What is the financial condition of Travere Therapeutics?

Travere Therapeutics maintains a robust financial condition supported by a strong pipeline and successful clinical trials.

How does Travere Therapeutics develop its therapies?

Travere collaborates closely with the rare disease community to understand their needs and develops life-changing therapies based on these insights.

Where can more information about Travere Therapeutics be found?

More information can be found on their official website, travere.com.
Travere Therapeutics Inc

Nasdaq:TVTX

TVTX Rankings

TVTX Stock Data

2.05B
84.43M
0.65%
98.86%
11%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO